[go: up one dir, main page]

WO1998017253A1 - Procede et compositions utilises pour interrompre la fonction de la barriere epitheliale - Google Patents

Procede et compositions utilises pour interrompre la fonction de la barriere epitheliale Download PDF

Info

Publication number
WO1998017253A1
WO1998017253A1 PCT/US1997/019343 US9719343W WO9817253A1 WO 1998017253 A1 WO1998017253 A1 WO 1998017253A1 US 9719343 W US9719343 W US 9719343W WO 9817253 A1 WO9817253 A1 WO 9817253A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
inhibitor
inhibitors
synthesis
ceramide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/019343
Other languages
English (en)
Inventor
Peter M. Elias
Kenneth R. Feingold
Walter M. Holleran
Carl R. Thornfeldt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
DMK Pharmaceuticals Corp
Original Assignee
Cellegy Pharmaceuticals Inc
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellegy Pharmaceuticals Inc, University of California Berkeley, University of California San Diego UCSD filed Critical Cellegy Pharmaceuticals Inc
Priority to AU49193/97A priority Critical patent/AU4919397A/en
Publication of WO1998017253A1 publication Critical patent/WO1998017253A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Definitions

  • Conduritol B epoxide an inhibitor of ⁇ glucocerebrosidase, applied with fluindostatin very significantly increased stratum corneum water permeability but when combined with TOFA a significant increase in water permeability resulted.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention se rapporte à un procédé d'interruption de la fonction de la barrière épithéliale d'un hôte nécessitant l'administration topique d'une substance physiologiquement active. Ledit procédé consiste à appliquer sur l'épithélium de l'hôte une quantité suffisant à interrompre la barrière épithéliale d'au moins un agent choisi dans le groupe composé d'un inhibiteur de synthèse de céramide, d'un inhibiteur de synthèse d'acylcéramide, d'un inhibiteur de synthèse de glucosylcéramide, d'un inhibiteur de synthèse de sphingomyéline, d'un inhibiteur de synthèse d'acides gras et d'un inhibiteur de synthèse de cholestérol, d'une enzyme de dégradation de céramides, d'acylcéramide, de glucosylcéramides ou de sphingomyéline, d'un inhibiteur de phospholipide, de glycosphingolipide, dont la dégradation de glucosylcéramide, d'acylcéramide ou de sphingomyéline, et des inhibiteurs et les stimulateurs d'enzymes métaboliques d'acides gras libres, de céramide et de cholestérol. L'invention se rapporte également à une composition topique utilisée pour ledit procédé.
PCT/US1997/019343 1996-10-23 1997-10-22 Procede et compositions utilises pour interrompre la fonction de la barriere epitheliale Ceased WO1998017253A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU49193/97A AU4919397A (en) 1996-10-23 1997-10-22 Method and compositions for disrupting the epithelial barrier function

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73371296A 1996-10-23 1996-10-23
US08/733,712 1996-10-23

Publications (1)

Publication Number Publication Date
WO1998017253A1 true WO1998017253A1 (fr) 1998-04-30

Family

ID=24948821

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/019343 Ceased WO1998017253A1 (fr) 1996-10-23 1997-10-22 Procede et compositions utilises pour interrompre la fonction de la barriere epitheliale

Country Status (2)

Country Link
AU (1) AU4919397A (fr)
WO (1) WO1998017253A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001011009A3 (fr) * 1999-07-23 2002-09-12 Gauldie Jack Therapie genique intestinale
EP1534213A4 (fr) * 2002-03-13 2005-10-26 Collagenex Pharm Inc Systemes d'administration a base aqueuse
WO2008058034A1 (fr) * 2006-11-03 2008-05-15 Qlt Inc. Procédés de traitement de troubles ou d'affections dermatologiques
US7825104B2 (en) * 2001-07-23 2010-11-02 Ramot At Tel Aviv University Ltd. Methods and compositions for treating fungal infections
JP2012521376A (ja) * 2009-03-25 2012-09-13 コグニス・アイピー・マネージメント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング クエン酸カルシウムおよびｎ−アシル化アミノアルコール誘導体を含んでなる乾燥皮膚および皮膚老化の兆候を防ぐための化粧品組成物
US8884034B2 (en) 2009-07-08 2014-11-11 Dermira (Canada), Inc. TOFA analogs useful in treating dermatological disorders or conditions
US10406088B2 (en) 2015-01-20 2019-09-10 TetraDerm Group LLC Versatile topical drug delivery vehicle and multifactorial tissue moisturizer that provides mucosal and skin barrier restoration

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021230A1 (fr) * 1993-03-19 1994-09-29 Cellegy Pharmaceuticals, Inc. Procedes et compositions permettant de desorganiser le fonctionnement de la barriere epitheliale

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021230A1 (fr) * 1993-03-19 1994-09-29 Cellegy Pharmaceuticals, Inc. Procedes et compositions permettant de desorganiser le fonctionnement de la barriere epitheliale

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001011009A3 (fr) * 1999-07-23 2002-09-12 Gauldie Jack Therapie genique intestinale
US7825104B2 (en) * 2001-07-23 2010-11-02 Ramot At Tel Aviv University Ltd. Methods and compositions for treating fungal infections
EP1534213A4 (fr) * 2002-03-13 2005-10-26 Collagenex Pharm Inc Systemes d'administration a base aqueuse
US8029810B2 (en) 2002-03-13 2011-10-04 Thomas Skold Water-based delivery systems
WO2008058034A1 (fr) * 2006-11-03 2008-05-15 Qlt Inc. Procédés de traitement de troubles ou d'affections dermatologiques
JP2012521376A (ja) * 2009-03-25 2012-09-13 コグニス・アイピー・マネージメント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング クエン酸カルシウムおよびｎ−アシル化アミノアルコール誘導体を含んでなる乾燥皮膚および皮膚老化の兆候を防ぐための化粧品組成物
US8884034B2 (en) 2009-07-08 2014-11-11 Dermira (Canada), Inc. TOFA analogs useful in treating dermatological disorders or conditions
US9434718B2 (en) 2009-07-08 2016-09-06 Dermira (Canada), Inc. TOFA analogs useful in treating dermatological disorders or conditions
US9782382B2 (en) 2009-07-08 2017-10-10 Dermira (Canada), Inc. TOFA analogs useful in treating dermatological disorders or conditions
US10406088B2 (en) 2015-01-20 2019-09-10 TetraDerm Group LLC Versatile topical drug delivery vehicle and multifactorial tissue moisturizer that provides mucosal and skin barrier restoration

Also Published As

Publication number Publication date
AU4919397A (en) 1998-05-15

Similar Documents

Publication Publication Date Title
US6190894B1 (en) Method and compositions for disrupting the epithelial barrier function
US6010691A (en) Methods for enhancing permeation of a topically administered physiologically active substance
WO1994021230A1 (fr) Procedes et compositions permettant de desorganiser le fonctionnement de la barriere epitheliale
CA1223818A (fr) Composes pharmaceutiques penetrantes a usage topique contenant du n-(2-hydroxyethyl) pyrrolidone
US5993836A (en) Topical anesthetic formulation
CN100482216C (zh) 氢氧根释放剂增强透皮渗透的用途
CA1223819A (fr) Compositions pharmaceutiques penetrantes a action locale, renfermant du 1-dodecyl-azacycloheptan-2-one
US9308203B2 (en) Pressure sensitive adhesive matrix device or system for the treatment or prevention of onychomycosis or tinea pedis
JP2003532629A (ja) 第４アンモニウム塩の経皮薬剤放出への使用
WO1996029988A1 (fr) Formulation topique pour la liberation locale d'un agent pharmaceutiquement actif
JP2008506767A (ja) 発毛を刺激する製剤
US20210338599A1 (en) Transdermal delivery formulation
CA2386720C (fr) Formulation pour un anesthesique topique et mode d'application
IL109036A (en) Preparations for detachment of the epithelial barrier function and use of means for the preparation of such preparations
US5932227A (en) Percutaneously administrable base composition and drug composition prepared therefrom
EP0216303B1 (fr) Médicament à usage externe
CZ240297A3 (cs) Transdermální přípravek
GB2497728A (en) Statin formulations for transmucosal delivery
WO1998017253A1 (fr) Procede et compositions utilises pour interrompre la fonction de la barriere epitheliale
WO1996025154A1 (fr) Formulation transdermique
WO1996025042A1 (fr) Formulation transdermique
EP0764017A1 (fr) Procedes et compositions permettant d'induire une separation de phase dans des doubles couches lipidiques epitheliales
US20050002868A1 (en) Method of treatment of a female suffering from androgen insufficiency
EA007351B1 (ru) Фармацевтическая композиция для чрескожной доставки физиологически активных агентов
US9744156B2 (en) Methods and compositions for enhanced transungual delivery of AR-12

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA